01/10/2025
7:06 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:19 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
11/05/2024
7:33 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/05/2024
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
3:34 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
10/03/2024
7:58 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
7:57 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/06/2024
3:52 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
08/06/2024
3:54 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2024
3:30 PM | Inozyme Pharma (Issuer)
Mathers Edward T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for INZY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. |
06/20/2024
3:15 PM | Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
3:20 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
7:32 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
7:33 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/08/2024
5:44 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/12/2024
7:34 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/12/2024
7:40 AM | Inozyme Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/12/2024
7:32 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
6:11 PM | Inozyme Pharma (Subject)
Sofinnova Venture Partners X, L.P. (Filed by)
| Form SC 13D/A | |
02/14/2024
7:34 PM | Inozyme Pharma (Subject)
Venrock Healthcare Capital Partners II, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
5:08 PM | Inozyme Pharma (Subject)
New Enterprise Associates 15, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
12:40 PM | Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
| Form SC 13G | |
02/14/2024
10:54 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
02/14/2024
7:48 AM | Deep Track Capital, LP (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
02/12/2024
8:06 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
